Studies AccessILD

AccessILD

A next-generation registry of patients with Interstitial Lung Disease (ILD)

AccessILD is a next-generation registry that interacts directly with patients via online questionnaires and other remote testings, to create a rich database of disease-relevant information that can be used to support research into ILD. AccessILD participants are also offered additional patient-specific research opportunities; your practice will receive payment for each patient enrolled in these sub-studies with no further input required from your practice staff.

  • Generate ongoing revenue: You’ll receive payment from multiple research opportunities offered to patients within the registry.
  • No additional workload for the practice: Approve patients for the registry in one click, we re-engage patients for sub-studies with no additional input from you.
  • Help improve patient access to research: GP participation supports reach to a wider patient demographic, providing research opportunities for patients from all backgrounds.

AccessILD is part of uMed’s ACCESS Cohort programme which currently also includes registries of patients with Parkinson’s Disease (AccessPD) and Cardiometabolic Disease (AccessCMD).

Key Study
Information

  • Treatment area:

    Interstitial Lung Diseases (ILD)

  • Study type:

    Longitudinal, observational, fully remote study, utilising uMed’s technology to collect EHR & PROs

  • Study aim:

    To advance our understanding of Interstitial Lung Disease and accelerate the development of advanced therapies to improve outcomes for patients

  • Recruitment target:

    Ongoing patient recruitment of patient's diagnosed with Interstitial Lung Disease

  • Practice payment:

    Details of practice revenue available on request